PAR-25-032-Full-Announcement.html

This is a Notice of Funding Opportunity (NOFO) for the NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional), issued by the Department of Health and Human Services National Institutes of Health. The funding opportunity (PAR-25-032) aims to support research necessary for planning Phase II-IV clinical trials focused on prevention and treatment of heart, lung, blood, and sleep disorders. The R34 mechanism is specifically designed to answer scientific or operational questions that will inform the development of future clinical trials, though any subsequent trials will require new applications for support.

The opportunity is open to a wide range of applicants including state and local governments, tribal organizations, higher education institutions, nonprofits, and for-profit organizations. It falls under five CFDA programs: Lung Diseases Research (93.838), Cardiovascular Diseases Research (93.837), Translation and Implementation Science Research (93.840), Blood Diseases and Resources Research (93.839), and the National Center on Sleep Disorders Research (93.233). The research must provide results sufficient to inform future trials without requiring additional studies, focusing on interventions in heart, lung, blood, and sleep disorders. This differs from standard trial start-up funding by requiring new scientific or operational insights rather than just trial preparation.